BR112017027639A2 - epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceres - Google Patents
epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceresInfo
- Publication number
- BR112017027639A2 BR112017027639A2 BR112017027639A BR112017027639A BR112017027639A2 BR 112017027639 A2 BR112017027639 A2 BR 112017027639A2 BR 112017027639 A BR112017027639 A BR 112017027639A BR 112017027639 A BR112017027639 A BR 112017027639A BR 112017027639 A2 BR112017027639 A2 BR 112017027639A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- cell epitopes
- cells
- immunotherapy
- relates
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
a presente invenção refere-se a peptídeos, proteínas, ácidos nucleicos e células para utilização em métodos de imunoterapia. mais especificamente, a presente invenção refere-se à imunoterapia do câncer, mieloma em particular. a presente invenção refere-se também a epítopos de peptídeos obtidos de células t associadas a tumores, isoladamente ou combinados com outros peptídeos associados a tumores, que podem, por exemplo, atuar como ingredientes farmacêuticos ativos de composições vacinais que estimulam respostas imunes antitumorais ou que estimulam células t ex vivo, que são depois transferidas a pacientes. peptídeos, quer ligados a moléculas do complexo principal de histocompatibilidade (mhc) ou peptídeos como tal, também podem ser alvos de anticorpos, de receptores de células t solúveis e de outras moléculas ligantes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184500P | 2015-06-25 | 2015-06-25 | |
GBGB1511191.7A GB201511191D0 (en) | 2015-06-25 | 2015-06-25 | T-cell epitopes for the immunotherapy of myeloma |
PCT/EP2016/064317 WO2016207164A2 (en) | 2015-06-25 | 2016-06-21 | Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017027639A2 true BR112017027639A2 (pt) | 2018-09-11 |
Family
ID=53872214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017027639A BR112017027639A2 (pt) | 2015-06-25 | 2016-06-21 | epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceres |
Country Status (18)
Country | Link |
---|---|
US (2) | US10196422B2 (pt) |
EP (1) | EP3313860A2 (pt) |
JP (1) | JP2018520653A (pt) |
KR (1) | KR20180012865A (pt) |
CN (1) | CN107889489A (pt) |
AU (1) | AU2016284857A1 (pt) |
BR (1) | BR112017027639A2 (pt) |
CA (1) | CA2990507A1 (pt) |
CR (1) | CR20180051A (pt) |
EA (1) | EA201792484A1 (pt) |
GB (1) | GB201511191D0 (pt) |
IL (1) | IL255932A (pt) |
MA (5) | MA46506A1 (pt) |
MX (1) | MX2017016207A (pt) |
PE (1) | PE20180174A1 (pt) |
SG (1) | SG10202001488VA (pt) |
TW (1) | TW201710289A (pt) |
WO (1) | WO2016207164A2 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
NZ721908A (en) | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
EP3362929B1 (en) * | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
US11585805B2 (en) | 2016-02-19 | 2023-02-21 | Nantcell, Inc. | Methods of immunogenic modulation |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
AU2017305396A1 (en) * | 2016-08-02 | 2019-02-21 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
JP2020510038A (ja) * | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
WO2018189152A2 (en) * | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
KR20190137858A (ko) | 2017-04-10 | 2019-12-11 | 이매틱스 바이오테크놀로지스 게엠베하 | 백혈병 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합 |
WO2018224166A1 (en) * | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
DK3428194T3 (da) | 2017-07-14 | 2021-11-15 | Immatics Biotechnologies Gmbh | Forbedret polypeptidmolekyle med dobbelt specificitet |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
CN107937515B (zh) * | 2017-12-06 | 2018-11-09 | 北京泱深生物信息技术有限公司 | 一种阿尔茨海默的诊疗基因靶点及其应用 |
AU2019218093A1 (en) | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
WO2020047138A1 (en) * | 2018-08-29 | 2020-03-05 | Amyris, Inc. | Cells and methods for selection based assay |
WO2020041876A1 (en) * | 2018-08-30 | 2020-03-05 | Université de Montréal | Proteogenomic-based method for identifying tumor-specific antigens |
WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
AU2020283500A1 (en) | 2019-05-27 | 2022-01-27 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
SG11202112561UA (en) | 2019-06-06 | 2021-12-30 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
CA3158692A1 (en) * | 2019-11-18 | 2021-05-27 | Epivax Therapeutics, Inc. | Improved neo-epitope vaccines and methods of treating cancer |
AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
KR102361479B1 (ko) * | 2020-06-18 | 2022-02-11 | 고려대학교 산학협력단 | siRNA의 생성 및 기능 증진 활성을 갖는 CMTR1의 신규용도 |
WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
CN113476619B (zh) * | 2021-07-08 | 2022-11-29 | 上海交通大学医学院附属仁济医院 | 一种18f标记纳米抗体探针及其制备方法和应用 |
WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7368531B2 (en) * | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
DE60333732D1 (de) * | 2002-03-01 | 2010-09-23 | Immunomedics Inc | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen |
DE10360456A1 (de) * | 2003-12-22 | 2005-07-28 | Vaecgene Biotech Gmbh | Tumorantigene und deren Verwendung |
US7998695B2 (en) * | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
ATE440107T1 (de) | 2005-09-05 | 2009-09-15 | Immatics Biotechnologies Gmbh | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe |
US20100009463A1 (en) * | 2006-07-13 | 2010-01-14 | Peter Hornbeck | Reagents for the detection of protein phosphorylation in signaling pathways |
HUE025636T2 (en) * | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | New immunogenic epitope for immunotherapy |
UA103882C2 (uk) * | 2007-07-27 | 2013-12-10 | Імматікс Біотекнолоджіс Гмбх | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина |
US20100209427A1 (en) * | 2008-09-24 | 2010-08-19 | Yu Li | Lysine acetylation sites |
EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
EP3417874A1 (en) * | 2012-11-28 | 2018-12-26 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
WO2014200910A2 (en) * | 2013-06-10 | 2014-12-18 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
-
2015
- 2015-06-25 GB GBGB1511191.7A patent/GB201511191D0/en not_active Ceased
-
2016
- 2016-06-16 TW TW105118858A patent/TW201710289A/zh unknown
- 2016-06-21 JP JP2017560907A patent/JP2018520653A/ja active Pending
- 2016-06-21 WO PCT/EP2016/064317 patent/WO2016207164A2/en active Application Filing
- 2016-06-21 MA MA46506A patent/MA46506A1/fr unknown
- 2016-06-21 SG SG10202001488VA patent/SG10202001488VA/en unknown
- 2016-06-21 CA CA2990507A patent/CA2990507A1/en not_active Abandoned
- 2016-06-21 MA MA41521A patent/MA41521A1/fr unknown
- 2016-06-21 CR CR20180051A patent/CR20180051A/es unknown
- 2016-06-21 MA MA46504A patent/MA46504A1/fr unknown
- 2016-06-21 MA MA46508A patent/MA46508A1/fr unknown
- 2016-06-21 EP EP16732263.5A patent/EP3313860A2/en not_active Withdrawn
- 2016-06-21 BR BR112017027639A patent/BR112017027639A2/pt not_active Application Discontinuation
- 2016-06-21 EA EA201792484A patent/EA201792484A1/ru unknown
- 2016-06-21 MA MA46507A patent/MA46507A1/fr unknown
- 2016-06-21 MX MX2017016207A patent/MX2017016207A/es unknown
- 2016-06-21 KR KR1020187001628A patent/KR20180012865A/ko unknown
- 2016-06-21 CN CN201680037125.9A patent/CN107889489A/zh active Pending
- 2016-06-21 AU AU2016284857A patent/AU2016284857A1/en not_active Abandoned
- 2016-06-21 PE PE2017002495A patent/PE20180174A1/es unknown
- 2016-06-24 US US15/191,895 patent/US10196422B2/en active Active
-
2017
- 2017-11-26 IL IL255932A patent/IL255932A/en unknown
-
2018
- 2018-11-20 US US16/196,812 patent/US10377797B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016207164A2 (en) | 2016-12-29 |
TW201710289A (zh) | 2017-03-16 |
CN107889489A (zh) | 2018-04-06 |
CR20180051A (es) | 2018-05-25 |
MA41521A1 (fr) | 2018-06-29 |
KR20180012865A (ko) | 2018-02-06 |
US20190077832A1 (en) | 2019-03-14 |
MA46508A1 (fr) | 2021-09-30 |
JP2018520653A (ja) | 2018-08-02 |
MA46507A1 (fr) | 2021-03-31 |
SG10202001488VA (en) | 2020-04-29 |
US20170022251A1 (en) | 2017-01-26 |
EA201792484A1 (ru) | 2018-05-31 |
US10377797B2 (en) | 2019-08-13 |
IL255932A (en) | 2018-01-31 |
PE20180174A1 (es) | 2018-01-22 |
MA46504A1 (fr) | 2021-03-31 |
MX2017016207A (es) | 2018-07-06 |
WO2016207164A3 (en) | 2017-02-02 |
GB201511191D0 (en) | 2015-08-12 |
EP3313860A2 (en) | 2018-05-02 |
US10196422B2 (en) | 2019-02-05 |
CA2990507A1 (en) | 2016-12-29 |
MA46506A1 (fr) | 2021-03-31 |
AU2016284857A1 (en) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017027639A2 (pt) | epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceres | |
BR112017027459A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de ovário e outros cânceres | |
BR112018009980A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceres | |
BR112018015793A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra nhl e de outros cânceres | |
BR112017028558A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer epitelial de ovário e outros cânceres | |
BR112018008806A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia de diversos cânceres | |
BR112018001687A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de próstata e outros cânceres | |
BR112018003460A2 (pt) | peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres | |
BR112017019217A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pâncreas e outros cânceres | |
BR112018007206A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra leucemia linfocítica crônica (cll) e outros cânceres | |
BR112018016734A2 (pt) | peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres | |
BR112017019804A2 (pt) | peptídeos e combinações de peptídeos e arcabouços para uso na imunoterapia contra o carcinoma de células renais (ccr) e outros cânceres | |
BR112018017022A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão de células não pequenas e outros cânceres | |
BR112017017560A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere | |
BR112017017289A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra diversos tumores | |
BR112017028363A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de esôfago e outros cânceres | |
CO2017012891A2 (es) | Péptidos y combinaciones de péptidos para la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer | |
BR112018068489A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia anticâncer | |
BR112018073921A2 (pt) | peptídeos e combinações de peptídeos que servem como alvos e para uso na imunoterapia do câncer da vesícula biliar, do colangiocarcinoma e de outros cânceres | |
EA201792531A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака | |
CO2018002902A2 (es) | Péptidos y combinaciones de péptidos para el tratamiento inmunoterapéutico de varios tipos de cáncer | |
BR112019028070A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres | |
CO2018004869A2 (es) | Péptidos y combinación de péptidos para inmunoterapia contra varios tipos de cáncer | |
BR112019003513A2 (pt) | peptídeos e suportes para uso em imunoterapia de carcinoma de células escamosas de cabeça e pescoço e outros cânceres | |
CL2017002346A1 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |